|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0010583,
umls-concept:C0012133,
umls-concept:C0013089,
umls-concept:C0015133,
umls-concept:C0021051,
umls-concept:C0024305,
umls-concept:C0030705,
umls-concept:C0086418,
umls-concept:C0210630,
umls-concept:C0473169
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1996-12-17
|
|
pubmed:abstractText |
To determine the following: (1) the feasibility of combining the antiretroviral didanosine (ddl) with a 96-hour continuous intravenous (IV) infusion of cyclophosphamide (800 mg/m2), doxorubicin (50 mg/m2), and etoposide (240 mg/m2) (CDE) plus filgrastim in patients with non-Hodgkin's lymphoma (NHL) associated with human immunodeficiency virus (HIV) infection; (2) the effect of ddl on CDE-induced myelosuppression and CD4 lymphopenia; and (3) the effect of CDE on serum p24 antigen and quantitative HIV blood cultures.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3026-35
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8918501-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:8918501-Adult,
pubmed-meshheading:8918501-Anti-HIV Agents,
pubmed-meshheading:8918501-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8918501-CD4 Lymphocyte Count,
pubmed-meshheading:8918501-Cyclophosphamide,
pubmed-meshheading:8918501-Didanosine,
pubmed-meshheading:8918501-Doxorubicin,
pubmed-meshheading:8918501-Etoposide,
pubmed-meshheading:8918501-Female,
pubmed-meshheading:8918501-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:8918501-HIV,
pubmed-meshheading:8918501-HIV Core Protein p24,
pubmed-meshheading:8918501-Humans,
pubmed-meshheading:8918501-Lymphoma, AIDS-Related,
pubmed-meshheading:8918501-Lymphoma, Non-Hodgkin,
pubmed-meshheading:8918501-Male,
pubmed-meshheading:8918501-Middle Aged,
pubmed-meshheading:8918501-Pilot Projects,
pubmed-meshheading:8918501-Recombinant Proteins,
pubmed-meshheading:8918501-Survival Rate,
pubmed-meshheading:8918501-Viremia
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. sparano@jimmy.harvard.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
